Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Rifampicin-induced injury in L02 cells is alleviated by 4-PBA via inhibition of the PERK-ATF4-CHOP pathway
Rifampicin-induced antineutrophil cytoplasmic antibody-positive vasculitis: a case report and review of the literature
Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: Preparation and in vitro aerosol characterization
Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis
Rifampicin for Continuation Phase Tuberculosis Treatment in Uganda: A Cost-Effectiveness Analysis
Rifampin Drug Resistance Tests for Tuberculosis: Challenging the Gold Standard
Rifampin induced angioedema: a rare but serious side effect
Rifampin Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection
Rifampicin serum levels in childhood tuberculosis
Rifampin and rifaximin resistance in clinical isolates of Clostfdium diicile
Rifaximin and nonabsorbable disaccharides for hepatic encephalopathy
Rifaximin pharmacology and clinical implications
Rifaximin Improves Psychometric Performance and Health-Related Quality of Life in Patients With Minimal Hepatic Encephalopathy (The RIME Trial)
Rifaximin vs conventional oral therapy for hepatic encephalopathy: A meta-analysis
Rifaximin Therapy in Minimal Hepatic Encephalopathy Cirrhotics Response
Rifampin monoresistant tuberculosis and HIV comorbidity in California, 1993-2008: a retrospective cohort study
Rifampin Combination Therapy for Nonmycobacterial Infections
Rifampin resistance, Beijing-W clade-single nucleotide polymorphism cluster group 2 phylogeny, and the Rv2629 191-C allele in Mycobacterium tuberculosis strains
Rifampin Protects Human Lung Epithelial Cells Against Cytotoxicity Induced by Clinical Multi and Pandrug-resistant Acinetobacter baumannii
Rifamycin antibiotics-new compounds and synthetic methods. Part 4: Study of the reaction of 3-formylrifamycin SV with secondary amines and ketones
Rifampin and Methicillin-Resistant Staphylococcus aureus Bone and Joint Infections Reply
Rifapentine Is Not More Active than Rifampin against Chronic Tuberculosis in Guinea Pigs
Rifampin and Methicillin-Resistant Staphylococcus aureus Bone and Joint Infections
Rifapentine and Isoniazid for Latent Tuberculosis
Rifampicin-fosfomycin coating for cementless endoprostheses: Antimicrobial effects against methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA)
Rifampicin-resistance, rpoB polymorphism and RNA polymerase genetic engineering
Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia
Rifampin Heteroresistance in Mycobacterium tuberculosis Cultures as Detected by Phenotypic and Genotypic Drug Susceptibility Test Methods
Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert (R) MTB/RIF in Kampala, Uganda: a retrospective study
Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis
Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients
Rifampin Enhances the Glucose-Lowering Effect of Metformin and Increases OCT1 mRNA Levels in Healthy Participants
Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population
Rifampicin reduces advanced glycation end products and activates DAF-16 to increase lifespan in Caenorhabditis elegans
Rifampin Induces Hydroxyl Radical Formation in Mycobacterium tuberculosis
Rifampicin-Independent Interactions between the Pregnane X Receptor Ligand Binding Domain and Peptide Fragments of Coactivator and Corepressor Proteins
Rifampicin Loaded Mannosylated Cationic Nanostructured Lipid Carriers for Alveolar Macrophage-specific Delivery
Rifaximin in the Treatment of Irritable Bowel Syndrome Is There a High Risk for Development of Antimicrobial Resistance?
Rifaximin: New Therapeutic Indication and Future Directions
Rifampin plus Metronidazole for Clostridium difficile Infection
Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug-Drug Interaction Trial Design
Rifampicin-Activated Human Pregnane X Receptor and CYP3A4 Induction Enhance Acetaminophen-Induced Toxicity
Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy
Rifampicin enhances activity of daptomycin and vancomycin against both a polysaccharide intercellular adhesin (PIA)-dependent and -independent Staphylococcus epidermidis biofilm
Rifampicin does not significantly affect the expression of small heterodimer partner in primary human hepatocytes
Rifampicin alters the expression of reference genes used to normalize real-time quantitative RT-PCR data
Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells
Rifaximin and Minimal Hepatic Encephalopathy
Rifaximin Improves Driving Simulator Performance in a Randomized Trial of Patients With Minimal Hepatic Encephalopathy
Rifaximin in the treatment of inflammatory bowel disease
Rifampicin combined regimens for Gram-negative infections: data from the literature
Rifampin-Isoniazid Oligonucleotide Typing: an Alternative Format for Rapid Detection of Multidrug-Resistant Mycobacterium tuberculosis
Rifaximin: beyond the traditional antibiotic activity
Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Humans
Rifampicin treatment of canine pyoderma due to multidrug-resistant meticillin-resistant staphylococci: a retrospective study of 32 cases
Rifaximin Has No Effect on Hemodynamics in Decompensated Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled Trial
Rifampicin for Idiopathic Granulomatous Lobular Mastitis: A Promising Alternative for Treatment